Paradigm Biocapital Advisors LP Purchases Shares of 1,191,462 Metsera Inc. $MTSR

Key Points

• Paradigm Biocapital Advisors LP has purchased 1,191,462 shares in Metsera Inc. for approximately $32.4 million, making it the 19th largest position in their portfolio.
• Several analysts have recently upgraded their ratings for Metsera, with Bank of America raising the target price to $50.00 and Guggenheim increasing it to $62.00, indicating strong market confidence.
• Metsera's stock has shown significant growth potential, with a fifty-two week low of $12.30 and a high of $47.40, currently trading at $35.29.

Paradigm Biocapital Advisors LP purchased a new position in Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,191,462 shares of the company's stock, valued at approximately $32,432,000. Metsera accounts for 1.5% of Paradigm Biocapital Advisors LP's portfolio, making the stock its 19th biggest holding. Paradigm Biocapital Advisors LP owned about 1.13% of Metsera at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Alphabet Inc. acquired a new position in shares of Metsera during the first quarter valued at $135,059,000. T. Rowe Price Investment Management Inc. acquired a new stake in Metsera in the 1st quarter worth approximately $78,748,000. Wellington Management Group LLP acquired a new position in shares of Metsera during the first quarter worth approximately $65,382,000. Alpha Wave Global LP bought a new stake in Metsera in the 1st quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Metsera during the first quarter worth $42,395,000.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MTSR. Cantor Fitzgerald restated an "overweight" rating on shares of Metsera in a research note on Wednesday. Guggenheim increased their price target on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Wells Fargo & Company began coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Wall Street Zen upgraded Metsera from a "sell" rating to a "hold" rating in a research note on Saturday, August 30th. Finally, Bank of America raised their target price on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $59.00.

Metsera Trading Down 2.2%

Shares of NASDAQ:MTSR traded down $0.79 during mid-day trading on Friday, reaching $35.50. 818,612 shares of the company traded hands, compared to its average volume of 1,013,763. Metsera Inc. has a 52 week low of $12.30 and a 52 week high of $47.40. The company's 50 day moving average price is $34.58 and its 200-day moving average price is $28.65.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.